Section Arrow
Quote
COAG.NASDAQ
- Hemab Therapeutics Holdings, Inc.
Quotes are at least 15-min delayed:2026/11/04 13:18 EST
Regular Hours
Last
 43.55
+0.45 (+1.04%)
Day High 
45 
Prev. Close
43.1 
1-M High
44.36 
Volume 
184.98K 
Bid
43.43
Ask
43.68
Day Low
41.96 
Open
45 
1-M Low
27.38 
Market Cap 
2.01B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 38.36 
20-SMA 34.69 
50-SMA 37.67 
52-W High 55.42 
52-W Low 23.0001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.78/-2.81
Enterprise Value
2.01B
Balance Sheet
Book Value Per Share
9.72
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.2499+0.536+75.08%0.2PE
KPTIKaryopharm Therapeutics Inc.0.09+0.0017+1.93%-- 
GERNGeron Corp1.035+0.105+11.29%-- 
INOInovio Pharmaceuticals1.73+0.07+4.22%-- 
RXRXRecursion Pharmaceuticals3.89+0.21+5.71%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.